2025 European Society for Medical Oncology (ESMO) Annual Congress: Presentation of Subgroup Analysis Results from the Phase 2 Clinical Trial of <i>Nanvuranlat</i> Suggesting Patient Selection Criteria for the Global Phase 3 Clinical Trial

Notice of Resignation of Representative Director Keiichi Masuya and New Management Structure

J-Pharma Raises an Additional 470 Million Yen Through Third-Party Allotment and Exercise of Stock Option Rights – Total Funding Reaches Approximately 13.4 Billion Yen